Clinical and Immunological Status of Lymphoma-Bearing Monkeys (4, 8503, OD5, 208, S1) Compared With That of Monkeys Which Did Not Develop Lymphomas (C1, 8302, H8, OD3, 203)
Monkey Code . | Treatment . | SIV Strain* . | Ab Anti-SIV-151 . | VC-152 . | PCR-153 . | Time to Death After Infection (wk) . | SIV Disease . | Immune Status-155 (before death) . | Lymphoma . | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
CD20+ . | CD2+ . | CD4+ . | CD8+ . | |||||||||
4 | Vaccinated¶ | SIVmac251 | 4.4 | + | + | 81 | Chronic | 340 | 1,500 | 210 | 1,710 | + |
8503 | Vaccinated | SIVmac251/32H | 4.4 | + | + | 139 | Chronic | 500 | 780 | 80 | 790 | + |
OD5# | Naive infected | SIVmac251 | 4.7 | + | + | 124 | Chronic | 670 | 9,450 | 200 | 10,040 | + |
208 | Naive infected | SIVmac251/32H | 5.0 | + | + | 94 | Chronic | 380 | 1,590 | 50 | 440 | + |
S1 | Naive infected | SIVmac251/32H | <2.0 | + | + | 12 | Acute | 248 | 1,292 | 795 | 745 | + |
C1 | Vaccinated | SIVmac251/32H | 5.0 | + | + | 106 | Chronic | 380 | 1,140 | 80 | 1,220 | − |
8302 | Vaccinated | SIVmac251/32H | 5.0 | + | + | 125 | Chronic | 190 | 650 | 200 | 480 | − |
OD3 | Naive infected | SIVmac251 | 5.3 | + | + | 71 | Chronic | 540 | 1,560 | 390 | 1,510 | − |
203 | Naive infected | SIVmac251/32H | 5.0 | + | + | 66 | Chronic | 680 | 1,020 | 20 | 1,330 | − |
H8 | Naive infected | SIVmac251/32H | <2.0 | + | + | 16 | Acute | 849 | 3,184 | 1,592 | 1,432 | − |
Monkey Code . | Treatment . | SIV Strain* . | Ab Anti-SIV-151 . | VC-152 . | PCR-153 . | Time to Death After Infection (wk) . | SIV Disease . | Immune Status-155 (before death) . | Lymphoma . | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
CD20+ . | CD2+ . | CD4+ . | CD8+ . | |||||||||
4 | Vaccinated¶ | SIVmac251 | 4.4 | + | + | 81 | Chronic | 340 | 1,500 | 210 | 1,710 | + |
8503 | Vaccinated | SIVmac251/32H | 4.4 | + | + | 139 | Chronic | 500 | 780 | 80 | 790 | + |
OD5# | Naive infected | SIVmac251 | 4.7 | + | + | 124 | Chronic | 670 | 9,450 | 200 | 10,040 | + |
208 | Naive infected | SIVmac251/32H | 5.0 | + | + | 94 | Chronic | 380 | 1,590 | 50 | 440 | + |
S1 | Naive infected | SIVmac251/32H | <2.0 | + | + | 12 | Acute | 248 | 1,292 | 795 | 745 | + |
C1 | Vaccinated | SIVmac251/32H | 5.0 | + | + | 106 | Chronic | 380 | 1,140 | 80 | 1,220 | − |
8302 | Vaccinated | SIVmac251/32H | 5.0 | + | + | 125 | Chronic | 190 | 650 | 200 | 480 | − |
OD3 | Naive infected | SIVmac251 | 5.3 | + | + | 71 | Chronic | 540 | 1,560 | 390 | 1,510 | − |
203 | Naive infected | SIVmac251/32H | 5.0 | + | + | 66 | Chronic | 680 | 1,020 | 20 | 1,330 | − |
H8 | Naive infected | SIVmac251/32H | <2.0 | + | + | 16 | Acute | 849 | 3,184 | 1,592 | 1,432 | − |
*SIV strain used to infect the monkeys. SIVmac251/32H derived from an in vivo passage of SIVmac251.
End-point anti-SIV antibody titers detected by ELISA.
Viral isolation by coculture with C8166 human T-cell line.
PCR DNA analysis using primers amplifying the gag region of SIV.
Number of CD20+, CD2+, CD4+, and CD8+ cells (×103/mL) as determined from the last bleeding before death.
¶Formalin-inactivated whole SIV derived from HUT-78 chronically infected cells.
#Monkey OD5 was splenectomized 1 year after infection.